Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2000-6-29
|
| pubmed:abstractText |
Androgen-independent growth of prostate cancer is correlated with expression of bcl-2. The impact of bcl-2 expression on the growth of prostate cancer cells following androgen ablation, was examined in the androgen-sensitive prostatic carcinoma cell line, LNCaP. Vector control and bcl-2 expressing LNCaP cells were grown subcutaneously in male nude mice. Tumor volume, apoptosis, and proliferation were assessed following castration. The levels of c-myc, p53, p21, bax, and bcl-2 protein were assessed by Western blotting. Bcl-2 expressing tumors exhibited a significant augmentation in growth compared to controls (p 0.01). No difference in the spontaneous rate of proliferation was observed between bcl-2 and control tumors, however, bcl-2 expressing tumors exhibited lower rates of apoptosis. Following orchiectomy the apoptotic index remained significantly lower in bcl-2 expressing tumors (p 0.002 at day 3). The proliferative index was maintained in bcl-2 expressing, but not control tumors following castration. This resulted in a significant growth advantage in bcl-2 tumors subsequent to androgen ablation (p 0.001). These changes were accompanied by alterations in the levels of gene products known to regulate the cell cycle and/or apoptosis. These results emphasize the significance of bcl-2 expression during prostate cancer progression and suggest possible mechanisms for the acquisition of androgen-independent tumor growth.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Androgens,
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Recombinant,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-bcl-2,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-myc,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Protein p53
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
1107-3756
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
1
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
953-9
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:9852630-Androgens,
pubmed-meshheading:9852630-Animals,
pubmed-meshheading:9852630-Apoptosis,
pubmed-meshheading:9852630-Blotting, Western,
pubmed-meshheading:9852630-Castration,
pubmed-meshheading:9852630-Cell Division,
pubmed-meshheading:9852630-DNA, Recombinant,
pubmed-meshheading:9852630-Genetic Vectors,
pubmed-meshheading:9852630-Humans,
pubmed-meshheading:9852630-Male,
pubmed-meshheading:9852630-Mice,
pubmed-meshheading:9852630-Mice, Nude,
pubmed-meshheading:9852630-Neoplasm Transplantation,
pubmed-meshheading:9852630-Prostatic Neoplasms,
pubmed-meshheading:9852630-Proto-Oncogene Proteins c-bcl-2,
pubmed-meshheading:9852630-Proto-Oncogene Proteins c-myc,
pubmed-meshheading:9852630-Transplantation, Heterologous,
pubmed-meshheading:9852630-Tumor Cells, Cultured,
pubmed-meshheading:9852630-Tumor Suppressor Protein p53
|
| pubmed:year |
1998
|
| pubmed:articleTitle |
Molecular correlates of bcl-2-enhanced growth following androgen-ablation in prostate carcinoma cells in vivo.
|
| pubmed:affiliation |
Department of Molecular Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|